Program
povorcitinib
Also written as “Povorcitinib” and “INCB054707”.
Its studies are mostly in Hidradenitis Suppurativa · Prurigo · Vitiligo · Renal Insufficiency · Asthma, led by Incyte.
Drug pagePovorcitinib: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 238 open or running | phase 3since Nov 10, 2022 | May 24, 2018 | Nov 20, 2026phase 2 · NCT05851443 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since May 24, 2018.
- Sep 27, 2021Phase 1 study in Healthy ParticipantsNCT05068466 · 30 enrolled · Japan
- Jan 25, 2022Named povorcitinibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, INCB054707
- Nov 10, 20222 phase 3 studies in Hidradenitis SuppurativaNCT05620836, NCT05620823
- Nov 11, 20222 phase 1 studies in Renal InsufficiencyNCT05624723, NCT05624710
- Apr 24, 2023Phase 2 study in AsthmaNCT05851443 · 247 enrolled · United States, Argentina, Canada and more
- Jun 26, 2023Phase 2 study in UrticariaNCT05936567 · 136 enrolled · United States, Germany, Poland
- Oct 27, 20232 phase 3 studies in NonSegmental VitiligoNCT06113471, NCT06113445
- Jan 9, 2024Phase 3 study in Hidradenitis SuppurativaNCT06212999 · 617 enrolled · United States, Australia, Austria and more
- Apr 3, 2024Phase 1 study in Healthy ParticipantsNCT06380205 · 24 enrolled · United States
- May 29, 2024Phase 1 study in Healthy ParticipantsNCT06441318 · 128 enrolled · United States
- Jul 8, 2024Phase 1 study in Healthy ParticipantsNCT06505265 · 18 enrolled · United States
- Jul 18, 20242 phase 3 studies in Prurigo NodularisNCT06516965, NCT06516952
- Feb 26, 2025Phase 3 study in Hidradenitis SuppurativaNCT06855498 · 600 planned · United States, Argentina, Australia and more
- Oct 7, 2025Phase 2 study in Hidradenitis SuppurativaNCT07213973 · 40 planned · United States, Canada
- May 8, 2026Phase 1 study in Healthy ParticipantsNCT07588139 · 24 enrolled · United States
Ahead
- Nov 20, 2026Primary completion: phase 2 study in AsthmaNCT05851443
- Dec 26, 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06212999
- Feb 28, 2028Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06855498
- Mar 25, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07213973
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07588139Healthy Participants · United States | 1 | Completed | Sep 8, 2026 | 24 |
| NCT07213973Hidradenitis Suppurativa · United States, Canada | 2 | Recruiting | Mar 25, 2028 | 40 |
| NCT06855498Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Recruiting | Feb 28, 2028 | 600 |
| NCT06516965Prurigo Nodularis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 28, 2026 | 346 |
| NCT06516952Prurigo Nodularis · United States, Argentina, Austria and more | 3 | Active, not recruiting | Oct 19, 2026 | 349 |
| NCT06505265Healthy Participants · United States | 1 | Completed | Sep 18, 2024 | 18 |
| NCT06441318Healthy Participants · United States | 1 | Completed | Sep 10, 2024 | 128 |
| NCT06380205Healthy Participants · United States | 1 | Completed | Jun 7, 2024 | 24 |
| NCT06212999Hidradenitis Suppurativa · United States, Australia, Austria and more | 3 | Active, not recruiting | Dec 26, 2026 | 617 |
| NCT06113471NonSegmental Vitiligo · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | Mar 17, 2026 | 450 |
| NCT06113445NonSegmental Vitiligo · United States, Belgium, Canada and more | 3 | Active, not recruiting | Feb 24, 2026 | 467 |
| NCT05936567Urticaria · United States, Germany, Poland | 2 | Completed | Feb 28, 2025 | 136 |
| NCT05851443Asthma · United States, Argentina, Canada and more | 2 | Active, not recruiting | Nov 20, 2026 | 247 |
| NCT05624723Renal Insufficiency · United States, Germany | 1 | Completed | Feb 7, 2024 | 43 |
| NCT05624710Renal Insufficiency · United States, Germany | 1 | Completed | Jun 30, 2023 | 25 |
| NCT05620836Hidradenitis Suppurativa · United States, Australia, Bulgaria and more | 3 | Completed | Jan 7, 2025 | 619 |
| NCT05620823Hidradenitis Suppurativa · United States, Austria, Belgium and more | 3 | Completed | Feb 3, 2025 | 608 |
| NCT05068466Healthy Participants · Japan | 1 | Completed | Jan 25, 2022 | 30 |
| NCT05061693Prurigo Nodularis · United States, Canada, Germany and more | 2 | Completed | Aug 11, 2023 | 146 |
| NCT04818346NonSegmental Vitiligo · United States, Canada | 2 | Completed | May 24, 2022 | 171 |
| NCT04476043Hidradenitis Suppurativa · United States, Canada, France and more | 2 | Completed | Dec 15, 2021 | 209 |
| NCT03607487Hidradenitis Suppurativa · Canada, Denmark, Germany | 2 | Completed | Aug 13, 2019 | 35 |
| NCT03569371Hidradenitis Suppurativa · United States | 2 | Completed | Apr 22, 2019 | 10 |
How it is read
Names in the registry
- “Povorcitinib”, 13 entries
- “INCB054707”, 8 entries
- “povorcitinib”, 2 entries
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 8 studies
- Prurigo, 3 studies
- Vitiligo, 3 studies
- Renal Insufficiency, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.